2026-08-03 03:24:46
Latest Post
Keto Motors Signs MoUs with Three Major Mobility Operators to Deploy Up to 250 Electric Buses
InstaHelp by Urban Company crosses 100,000 daily delivered orders
Birla Cable Reports Stellar Q1 FY27 Results: Net Profit Soars to ₹30.70 Crore; Revenue Up 51.1% YoY to ₹266.64 Crore
Keto Motors to Launch Urbanova KE9, Marking Its Entry into India's Commercial Electric Bus Segment
3i Infotech Limited receives order worth Rs. 3.32 crores
Stock Report
GPCB Revokes Closure Notice for Aarti Drugs' Sayakha Plant; Operations Resume Following EDC Payment
Posted On : 2026-08-02 19:22:59( TIMEZONE : IST )
Active Pharmaceutical Ingredients (API) manufacturer Aarti Drugs Limited (BSE: 524348 | NSE: AARTIDRUGS) announced that the Gujarat Pollution Control Board (GPCB) has revoked its previous closure directions for the company's manufacturing facility in Sayakha, Gujarat.
The company confirmed receiving the official revocation order on July 31, 2026, allowing full resumption of operations at the site.
Background & Regulatory Chronology
Inspection Findings (June 20, 2026): GPCB conducted an inspection at Aarti Drugs' facility located at Plot No. DP-94 to DP-96, Saykha Industrial Estate, District Bharuch, Gujarat, where it cited certain non-compliances regarding the Water (Prevention and Control of Pollution) Act, 1974, and Consolidated Consents and Authorization (CCA) conditions.
Initial Closure Order: The regulatory body subsequently issued directions under Section 33A of the Water Act, mandating the shutdown of Amines manufacturing operations at the Sayakha unit effective 15 days from issuance.
Revocation Application & Resolution: Aarti Drugs formally applied to the GPCB seeking a revocation of the closure order after addressing the compliance observations and initiating corrective and preventive measures.
Order Receipt (July 31, 2026): The GPCB accepted the company's representation and formally issued the order revoking the closure directives.Environmental Damage Compensation (EDC): As an interim measure under the "Polluter Pays" principle and in line with Central Pollution Control Board (CPCB) guidelines, the GPCB levied an interim EDC of ₹10,20,000 (Rupees 10.20 Lakhs).
Payment Settlement: Aarti Drugs confirmed that it has already deposited the entire interim compensation amount of ₹10.20 Lakhs with the GPCB.
Impact Assessment: The management stated that the regulatory action and subsequent revocation cause no material impact on the overall financial, operational, or business activities of the company.
Shares of Aarti Drugs Limited was last trading in BSE at Rs. 423.50 as compared to the previous close of Rs. 412.60. The total number of shares traded during the day was 9820 in over 381 trades.
The stock hit an intraday high of Rs. 425.50 and intraday low of 412.75. The net turnover during the day was Rs. 4114849.00.
